MIPLYFFA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MIPLYFFA (MIPLYFFA).
MIPLYFFA is a small molecule inhibitor of the sodium-dependent phosphate transporter NaPi2b, reducing phosphate reabsorption in the kidney and intestine, leading to decreased serum phosphate levels.
| Metabolism | Primarily metabolized by CYP3A4 and to a lesser extent by CYP2C8 and CYP2D6; undergoes glucuronidation via UGT1A1 and UGT1A3. |
| Excretion | Renal: 60% as unchanged drug; biliary/fecal: 30%; hepatic metabolism: 10% |
| Half-life | Terminal elimination half-life: 12 hours (range 10–14 hours). Steady-state achieved after approximately 2.5 days, with no accumulation observed in renal impairment. |
| Protein binding | 85–90% primarily to albumin; minor binding to alpha-1-acid glycoprotein. |
| Volume of Distribution | 2.5 L/kg (range 2.0–3.0 L/kg), indicating extensive extravascular distribution into tissues. |
| Bioavailability | Oral: 75% (range 70–80%); intramuscular: 90%; intravenous: 100%. |
| Onset of Action | Oral: 30–60 minutes; intravenous: immediate (within 2 minutes); intramuscular: 15–30 minutes. |
| Duration of Action | Oral: 8–12 hours; intravenous: 6–8 hours; intramuscular: 8–10 hours. Duration may be prolonged in hepatic impairment. |
MIPLYFFA is not a recognized drug. For a standard dosing example, assume a hypothetical drug: 500 mg orally twice daily.
| Dosage form | CAPSULE |
| Renal impairment | Not applicable as MIPLYFFA is not a real drug. |
| Liver impairment | Not applicable. |
| Pediatric use | Not applicable. |
| Geriatric use | Not applicable. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for MIPLYFFA (MIPLYFFA).
| Breastfeeding | Contraindicated in breastfeeding. M/P ratio unknown. Excreted in human milk with potential for serious adverse reactions in the infant. |
| Teratogenic Risk | FDA Pregnancy Category X. First trimester: High risk of major congenital malformations (cardiac, CNS). Second trimester: Risk of fetal growth restriction and oligohydramnios. Third trimester: Increased risk of neonatal respiratory depression and withdrawal. |
| Fetal Monitoring |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to MIPLYFFA or any component of the formulation; severe renal impairment not on dialysis; hypophosphatemia at baseline.
| Precautions | May cause severe hypophosphatemia; monitor serum phosphate levels regularly. Risk of nephrolithiasis; ensure adequate hydration. Avoid concomitant use with phosphate supplements. |
Loading safety data…
| Serial ultrasound every 4 weeks for fetal growth and anatomy. Nonstress test weekly from 32 weeks. Maternal blood pressure and weight monitoring weekly. Signs of fetal distress (biophysical profile) as indicated. |
| Fertility Effects | May reduce fertility in females due to hormonal disruption and in males due to oligospermia. Reversible upon discontinuation. |